Lipid Toxicity in the Cardiovascular-Kidney-Metabolic Syndrome (CKMS)

Area of Science:

• Cardiovascular Medicine
• Nephrology
• Metabolic Disorders

Background:

• Cardiovascular-Kidney-Metabolic Syndrome (CKMS) is linked to elevated toxic lipids like ceramides, sphingolipids, and oxidized LDL.
• These lipids impair kidney and heart energy metabolism, crucial for homeostasis and cardiac function.
• Diastolic dysfunction and reduced renal filtration efficiency are associated with lipid accumulation.

Purpose of the Study:

• To elucidate the detrimental effects of specific lipid derivatives on cardiovascular and renal health.
• To highlight the role of lipid metabolism in cardiac energy production and renal tubular function.
• To underscore the potential benefits of lipid-lowering therapies in managing CKMS and protecting organ transplants.

Main Methods:

• Review of recent studies on lipid profiles in CKMS patients.
• Analysis of the impact of specific lipids on cellular energy metabolism in cardiac and renal tissues.
• Examination of the association between lipid deposition and organ dysfunction, including fibrosis and vascular pathology.

Main Results:

• Elevated ceramides, sphingolipids, oxidized LDL, and lipoproteins are toxic to kidney and heart.
• Impaired cardiac energy metabolism, particularly ATP availability, leads to diastolic dysfunction and heart failure.
• Lipid accumulation in renal tubules disrupts fuel/electrolyte resorption, and in glomeruli impairs filtration.
• Excessive adipose deposits and triglyceride accumulation contribute to vascular pathology and fibrosis in heart and kidneys.

Conclusions:

• Lipid toxicity significantly impacts cardiovascular and kidney function in CKMS.
• Maintaining optimal lipid control is essential for preventing organ damage and dysfunction.
• Lipid-lowering interventions show promise in preserving vital organ function pre- and post-transplantation.